Alpha 2.0
Login Register
» Authors » Dorota Borys

Dorota Borys

Explore the profile of Dorota Borys including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 67
Citations 920
Followers 0
Related Specialties
Allergy & Immunology
Pediatrics
General Medicine
Top 10 Co-Authors
Lode Schuerman
Nancy Francois
Magali Traskine
Marta Moreira
Javier Ruiz-Guinazu
Patricia Lommel
Fakrudeen Shafi
Kristien Swinnen
Roman Prymula
Juan Pablo Yarzabal
Published In
Vaccine
Hum Vaccin Immunother
Pediatr Infect Dis J
Expert Rev Vaccines
Lancet
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety, reactogenicity, and immunogenicity of a novel 24-valent pneumococcal vaccine candidate in healthy, pneumococcal vaccine-naïve Japanese adults: A phase 1 randomized dose-escalation trial
Borys D, Smulders R, Haranaka M, Nakano T, Chichili G, Ebara M, et al.
Vaccine . 2024 Nov; 44:126545. PMID: 39612802
Background: The burden of pneumococcal diseases remains high in Japan. Pn-MAPS24v is a novel MAPS-based vaccine containing complexes of 24 serotype-specific polysaccharides (PS), non-covalently coupled with fusion protein 1 (CP1)....
2.
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial
Borys D, Rupp R, Smulders R, Chichili G, Kovanda L, Santos V, et al.
Vaccine . 2024 Feb; 42(10):2560-2571. PMID: 38360475
Background: Pneumococcal conjugate vaccines (PCVs) significantly reduced pneumococcal disease burden. Nevertheless, alternative approaches for controlling more serotypes are needed. Here, the safety, tolerability, and immunogenicity of a 24-valent (1/2/3/4/5/6A/6B/7F/8/9N/9V/10A/11A/12F/14/15B/17F/18C/19A/19F/20B/22F/23F/33F) pneumococcal...
3.
Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020
Wu Q, Qian M, Welby S, Guignard A, Rosillon D, Gopala K, et al.
Hum Vaccin Immunother . 2023 Dec; 19(3):2283912. PMID: 38038626
Following the approval of for the immunization of girls and women in China against high-risk human papillomavirus types 16 and 18, a non-interventional post-authorization safety study was performed. A multi-center...
4.
MOnitoring human papillomavirus Vaccine effect on Infection and cErvical diseases (MOVIE): Protocol for a cohort study using electronic health records from Yinzhou, China
Deng S, Welby S, Liu Z, Yang Y, Meng R, Sun Y, et al.
Hum Vaccin Immunother . 2023 Oct; 19(2):2257989. PMID: 37813849
Cervical cancer is the fourth most common cancer in women, with a high disease burden worldwide. Human papillomavirus (HPV) vaccination reduces HPV-related infection and associated cervical lesions and cancers. Few...
5.
Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017-2021)
Eun B, Bahar E, Xavier S, Kim H, Borys D
Hum Vaccin Immunother . 2023 Mar; 19(1):2184756. PMID: 36896702
Human papillomavirus (HPV) infection is associated with the risk of developing certain cancers, including cancers of the cervix, vulva, vagina, penis, anus, rectum, and oropharynx. In 2016, the bivalent HPV-16/18...
6.
Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: A 10-year follow-up study
Zhao F, Jastorff A, Hong Y, Hu S, Chen W, Xu X, et al.
Asia Pac J Clin Oncol . 2022 Sep; 19(4):458-467. PMID: 36101936
Introduction: The pivotal efficacy study assessed efficacy and safety of GSK's AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years up to 6 years. The present extension study, performed 4 years...
7.
Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial
Rinta-Kokko H, Palmu A, Ruokokoski E, Nieminen H, Moreira M, Schuerman L, et al.
PLoS One . 2022 Jan; 17(1):e0261750. PMID: 34986178
Background: In the nation-wide double-blind cluster-randomised Finnish Invasive Pneumococcal disease trial (FinIP, ClinicalTrials.gov NCT00861380, NCT00839254), we assessed the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine...
8.
Progression from human papillomavirus (HPV) infection to cervical lesion or clearance in women (18-25 years): Natural history study in the control arm subjects of AS04-HPV-16/18 vaccine efficacy study in China between 2008 and 2016
Welby S, Rosillon D, Feng Y, Borys D
Expert Rev Vaccines . 2021 Dec; 21(3):407-413. PMID: 34939897
Background: Cervical cancer is the third most frequent cancer in Chinese women aged 15-44 years old. Human papillomavirus (HPV) is recognized as the main etiologic agent of cervical carcinomas. This...
9.
Can two different pneumococcal conjugate vaccines be used to complete the infant vaccination series? A randomized trial exploring interchangeability of the 13-valent pneumococcal conjugate vaccine and the pneumococcal non-typeable protein...
Mascarenas De Los Santos A, Rodriguez-Weber M, Sanchez-Marquez P, Traskine M, Carreno-Manjarrez R, Cervantes-Apolinar M, et al.
Expert Rev Vaccines . 2020 Dec; 19(11):995-1010. PMID: 33297773
We assessed the safety and immunogenicity of 2 + 1 infant regimens initiated with the 13-valent pneumococcal conjugate vaccine (PCV13) and completed with the pneumococcal non-typeable protein D-conjugate vaccine (PHiD-CV)....
10.
Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials
Nunes M, Moreira M, Koen A, van Niekerk N, Jose L, Cutland C, et al.
Expert Rev Vaccines . 2020 Nov; 19(12):1177-1189. PMID: 33245004
: We evaluated bacterial nasopharyngeal carriage (NPC) prevalence and cumulative acquisition following 7-valent pneumococcal conjugate vaccine (PCV7) or pneumococcal non-typeable protein D conjugate vaccine (PHiD-CV) administration. : Participants were children...